Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BW-20507 in chronic hepatitis B infection
ACTRN12623000708651Phase 2Active, not recruiting
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Start
- Jan 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of BW-20507 in hepatitis B (HBV) (6 arms), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of multiple doses of BW-20507 and Safety and tolerability of long-term multiple-dose BW-20507 treatment. Started Jan 2024; status: active, not recruiting.
02
Drugs
BW-20507
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ACTRN12623000708651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000708651.